Pet Rat Mycoplasmosis: Long-Term Management of Chronic Respiratory Disease

PublishedJuly 3, 2026Reading time13 minExoticRx Editorial

Editorially reviewed against published veterinary references. Awaiting credentialed clinical reviewer — our editorial process.

Clinical relevance

Murine respiratory mycoplasmosis (MRM), driven primarily by Mycoplasma pulmonis, is the most common chronic disease of pet rats (Rattus norvegicus) seen in small-animal practice. More than 90% of conventionally raised rats are colonized by adulthood, and clinical disease will eventually develop in a substantial fraction of those animals. Because M. pulmonis is acquired in the nest and transmitted horizontally between cagemates throughout life, any pet rat should be assumed infected unless it originated from a specific-pathogen-free colony — a vanishingly rare provenance for the pet trade.

MRM is therefore a condition to manage, not cure. Realistic goals: suppress active flares, slow bronchiectasis and pulmonary fibrosis, and preserve quality of life across a 2- to 3-year lifespan.

Pathophysiology

M. pulmonis is a wall-less prokaryote that adheres to ciliated respiratory epithelium from the nares through the bronchi and into the middle ear via the eustachian tube. It induces ciliostasis, epithelial hyperplasia, and lymphoplasmacytic submucosal infiltrate, remodeling over months to years into bronchiectasis, peribronchial cuffing, abscessation, and fibrosis. The absence of a peptidoglycan cell wall is clinically critical: beta-lactams (penicillins, cephalosporins) have no activity against mycoplasmas.

MRM is rarely monomicrobial. Intercurrent factors that convert colonization into clinical disease:

• Sendai virus (murine parainfluenza type 1) — synergistically worsens M. pulmonis lung lesions; rare in modern pet populations but present in some feeder lines.
• Cilia-associated respiratory (CAR) bacillus (Filobacterium rodentium) — disrupts mucociliary clearance.
• Streptococcus pneumoniae — potent secondary invader producing acute fibrinopurulent pneumonia in colonized lungs.
• Corynebacterium kutscheri — latent until stress or immunosuppression precipitates pulmonary abscessation.
• Environmental ammonia from soiled bedding — the single most modifiable husbandry factor; directly damages ciliated epithelium.
• Vitamin A/E deficiency, dusty bedding, low humidity, social stress — all implicated in lesion severity.

Transmission is vertical (in utero, nursing) and horizontal (aerosol, direct contact). By the time a pet rat reaches a clinic, the question is not exposure but expression.

Clinical signs and presentation

Stage by anatomic level.

Upper respiratory. Sneezing, "snuffling," red-brown crusting around eyes and nares. The latter is chromodacryorrhea — porphyrin secretion from the harderian gland, often misidentified by owners as bleeding. Non-specific for M. pulmonis but a reliable marker of illness or stress in rats.

Lower respiratory.

• Increased respiratory effort with an abdominal component
• Audible rales, wheezing, or "clicking" without a stethoscope
• Head bobbing synchronized with respiration — classic sign of significant dyspnea
• Cyanosis of extremities and pinnae in advanced disease
• Weight loss, hunched posture, piloerection, exercise intolerance

Otitis interna/media. M. pulmonis tracks up the eustachian tube into the bullae. Vestibular signs — head tilt, circling, nystagmus, rolling — may occur with or without overt respiratory disease and are a frequent presenting complaint. Otoscopy is rarely diagnostic.

Reproductive. M. pulmonis also causes salpingitis, pyometra, and infertility in does — assess reproductive tract in middle-aged intact females with chronic respiratory signs and a distended abdomen.

Diagnostic approach

MRM is overwhelmingly a clinical diagnosis in primary care. Chronic sneezing, chromodacryorrhea, audible airway sounds, and progressive dyspnea in a pet-bred rat are essentially pathognomonic, and confirmatory testing rarely changes the plan.

Clinical examination. Pediatric stethoscope; observation of respiratory effort with the rat unrestrained is more informative than any lab test. Document weight, body condition, and grip strength at every visit as objective trend markers.

Thoracic radiographs (two views). Useful in moderate-to-severe disease, primarily to rule out alternatives. Typical MRM findings: mottled bronchointerstitial pattern, peribronchial cuffing, hyperinflation, and — in advanced cases — pulmonary abscesses or bronchiectatic cavitations. Brief isoflurane or sevoflurane chamber induction with pre-oxygenation.

Critical rule-outs:

• Pulmonary neoplasia — bronchioloalveolar adenoma and adenocarcinoma are common in older rats and can be radiographically indistinguishable from chronic mycoplasmal disease. Postmortem-correlated radiographic studies indicate that cranial mediastinal lesions are significantly more suggestive of neoplasia.
• Cardiac disease — left-sided cardiomegaly with pulmonary edema; both myocardial and valvular disease occur with age.
• Pituitary adenoma with secondary respiratory compromise from neurologic decline.
• Bacterial bronchopneumonia (S. pneumoniae, Pasteurella pneumotropica, Bordetella bronchiseptica) — usually superimposed on MRM rather than alternative.

PCR. Oropharyngeal/nasopharyngeal swab PCR confirms colonization but not causation (>90% of asymptomatic rats are also positive). Useful for SPF colony screening; rarely indicated in pet practice. Tracheal wash and culture are rarely justified given anesthetic risk and the empirical treatment paradigm.

Antibiotic selection

Because mycoplasmas lack a cell wall, target therapy at intracellular and protein-synthesis machinery: fluoroquinolones, tetracyclines, macrolides, and chloramphenicol. Doses below are drawn from Carpenter's Exotic Animal Formulary, Quesenberry & Carpenter's Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery, the BSAVA Manual of Rodents and Ferrets, and Mitchell & Tully's Manual of Exotic Pet Practice. Where dose ranges differ between sources, the wider published range is given.

Enrofloxacin

• Dose: 5–10 mg/kg PO or SC q12h as monotherapy; 10–20 mg/kg PO q12h in combination protocols for established disease.
• Course: minimum 14 days; chronic cases routinely 4–6 weeks; refractory rats often maintained on long-term low-dose therapy.
• Notes: Bitter; do not give the parenteral formulation undiluted PO (oral mucosal ulceration). Compounded flavored oral suspension is preferred. Subcutaneous use causes sterile abscesses long-term — switch to oral once eating willingly. Cartilage concerns in juveniles are extrapolated from dogs and are low-priority in a 2-to-3-year-lifespan species.
• Evidence level: Strong — first-line in every major rodent reference.

Doxycycline

• Dose: 5 mg/kg PO q12h standard; up to 10 mg/kg PO q12h in severe or refractory cases.
• Course: 14–30 days minimum; combination with enrofloxacin is routine.
• Notes: Hyclate is bitter; monohydrate suspension is much better tolerated. Compounding pharmacies reliably produce a flavored 5–10 mg/mL suspension. Photosensitization is not clinically relevant in indoor pets.
• Evidence level: Strong — well-documented in vivo and in vitro activity against M. pulmonis.

Combination enrofloxacin + doxycycline

The de facto standard of care for clinically symptomatic MRM. Complementary mechanisms (DNA gyrase inhibition vs. 30S ribosomal blockade) and decades of clinical use.

• Typical regimen: enrofloxacin 10 mg/kg PO q12h + doxycycline 5 mg/kg PO q12h for 4–6 weeks, then reassess for step-down or pulse dosing.
• Evidence level: Strong by clinical consensus; controlled trials in pet-bred rats are limited.

Azithromycin

• Dose: 15–30 mg/kg PO q24h.
• Course: 10–21 days typical; can be used long-term given tissue accumulation.
• Notes: Compounded suspension generally well accepted (cherry-flavored human pediatric formulation is palatable). Useful when fluoroquinolones are not tolerated, in young growing rats where enrofloxacin is best avoided, and as a third agent in refractory disease. Excellent intracellular and pulmonary tissue penetration.
• Evidence level: Moderate — increasingly cited in current rodent texts; less long-term experience than enrofloxacin/doxycycline.

Chloramphenicol

Reserved for refractory disease, abscessating pneumonia, or first-line intolerance.

• Dose (palmitate, oral): 50 mg/kg PO q8h; 100–200 mg/kg q8h in severe disease per some formularies.
• Dose (sodium succinate, parenteral): 20–50 mg/kg SC q8–12h.
• Course: 14–21 days.
• Notes: Marrow suppression in the rat is dose-related and reversible; the irreversible idiosyncratic aplastic anemia of concern is a human risk. Owner counseling is mandatory — gloves when handling tablets, capsules, or suspension; avoid skin contact and aerosolization; pregnant or immunosuppressed household members should not handle the drug. Document the conversation. Prefer an alternative when feasible.
• Evidence level: Moderate — historical first-line, now reserved for resistant cases.

Tylosin and tilmicosin

• Tylosin 10 mg/kg PO or SC q12h has been used historically; injectable is irritating and oral palatability is poor.
• Tilmicosin 25 mg/kg SC appears in laboratory studies but is strongly discouraged in pet practice — documented cardiotoxicity, narrow therapeutic margin, and human accidental-injection fatalities. Current formularies recommend against routine use.
• Evidence level: Tylosin weak-to-moderate; tilmicosin weak with safety concerns dominant.

Course length and monitoring

Acute flares respond clinically within 5–10 days. Minimum 2–4 weeks of therapy; chronic established MRM often requires 6 weeks or longer, and many rats benefit from indefinite low-dose maintenance. Track weight weekly and resting respiratory rate (count for 60 s, undisturbed). Recurrence after discontinuation is the rule.

Adjunctive therapy

Antibiotics alone seldom produce a satisfactory result in moderate-to-severe MRM.

Bronchodilators. Many MRM rats have a measurable bronchospastic component during flares.

• Terbutaline: 0.01 mg/kg SC for acute bronchoconstriction; 0.1 mg/kg PO q8–12h ongoing. Owners can be taught SC administration for at-home crisis management.
• Aminophylline/theophylline: historically used; narrow margin in rats; largely supplanted by terbutaline.

Mucolytics. Nebulized N-acetylcysteine (10% solution, 2–3 mL into a small-volume nebulizer for 10–15 minutes q12–24h) mobilizes tenacious secretions in bronchiectasis. NAC is bronchoirritant in some patients — pretreat with a beta-agonist if cough worsens.

Nebulization. A well-tolerated adjunct delivered in a small enclosed chamber (commercial nebulization box, vented plastic carrier, or pediatric face-tent setup) for 15–30 minutes q8–24h.

• Sterile saline (0.9%): humidification alone improves mucociliary clearance — safest starting point.
• F10SC: 1:250 dilution in sterile water, 15–30 minutes BID. Widely used in exotic respiratory disease; safety profile excellent though rat-specific evidence is anecdotal.
• Gentamicin: 5 mg in 5 mL sterile saline BID. Local airway delivery with minimal systemic absorption; useful when secondary gram-negative overgrowth is suspected.
• Amikacin or enrofloxacin nebulization protocols exist but are less commonly used.

Counsel owners that nebulization supports, but does not replace, systemic antibiotics.

Anti-inflammatory therapy.

• Meloxicam: 1–2 mg/kg PO or SC q24h is now the standard analgesic/anti-inflammatory dose (the historic 0.2 mg/kg figure is widely accepted as subtherapeutic). For chronic airway inflammation and pleuritic pain, 1 mg/kg PO q24h is a reasonable maintenance dose; monitor GI and renal function in geriatrics.
• Corticosteroids: controversial. A short course of dexamethasone (0.5–1 mg/kg SC/IM single dose, or 0.1–0.5 mg/kg PO q24h tapered over 5–7 days) can break a severe inflammatory crisis. Do not combine with NSAIDs, and ensure active antibiotic cover during use. Long-term steroids are not appropriate.

Oxygen. 40–60% in an induction chamber or pediatric incubator stabilizes the cyanotic, decompensating rat for transport, imaging, or first-dose therapy.

Fluids and nutrition. SC LRS or Plasma-Lyte 50–100 mL/kg/day in divided doses; critical-care liquid diet (omnivore formulas, or Oxbow Critical Care) by syringe q4–6h in inappetent patients.

Husbandry intervention

No drug regimen succeeds without environmental correction; this conversation should accompany every MRM diagnosis and is often the most consequential intervention.

• Bedding. Eliminate pine and cedar shavings — volatile aromatic hydrocarbons (phenols, terpenes) are directly cytotoxic to respiratory epithelium. Use paper-based bedding (Carefresh, Yesterday's News), aspen, or hemp. Full change weekly minimum; spot-clean urine corners every 2–3 days.
• Ammonia control. The single most modifiable trigger for flares. Improve ventilation, reduce group size, increase bedding depth, clean more frequently. Owner test: kneel at cage level and inhale — if you can smell ammonia, the rat is breathing it at much higher concentration.
• Cage design. Wire-bottom cages are unacceptable. Solid floors with vertical space and cross-ventilation. Aquariums and closed tubs concentrate ammonia and are inappropriate for any rat with respiratory disease.
• Group composition. Rats are obligate social animals; isolation produces chronic stress and exacerbates MRM. Do not separate an affected rat from compatible cagemates without specific quarantine indication. A bonded pair or trio is the goal; avoid overcrowding and unstable male groupings.
• Quarantine. New rats: 2–3 weeks in a separate airspace (not just a separate cage in the same room). Goal is detection of acute respiratory disease and parasites before integration, not exclusion of M. pulmonis (which most pet-trade rats already carry).
• Air quality and humidity. No aerosol products, scented candles, cooking smoke, or tobacco smoke in the rat's airspace. HEPA filtration is a defensible recommendation for chronic patients. Maintain 40–60% relative humidity; dry heated indoor air worsens signs.

Long-term management and prognosis

MRM is a progressive structural disease. Therapy suppresses inflammation, controls secondary infection, and slows remodeling but does not reverse established bronchiectasis or fibrosis. Set this expectation at the first visit.

Frame prognosis by stage:

• Mild upper-airway disease (intermittent sneezing, occasional chromodacryorrhea, normal exercise tolerance) — many rats live a normal lifespan with husbandry correction and short antibiotic courses for flares.
• Established lower-airway disease (chronic increased respiratory effort, weight maintained) — months to over a year of good quality of life with combination antibiotics, adjunctive support, and disciplined husbandry.
• Advanced disease (continuous dyspnea at rest, weight loss, head tilt) — weeks to a few months; conversation shifts to palliation and humane endpoint planning.

Document a written rescue plan with the owner: which signs warrant a same-day call (acute increase in respiratory effort, cyanosis, anorexia, sudden head tilt), which can be managed at home with an additional dose of an existing medication, and which trigger an end-of-life discussion. Many owners benefit from having injectable terbutaline and pre-measured meloxicam at home for flare management.

Re-examine stable rats every 2–3 months and flaring rats more often. Body weight and resting respiratory rate are the two most useful objective trend markers.

When to refer

Most pet rat MRM is appropriately managed in primary care. Refer to an exotic-mammal specialist or board-certified zoological-companion-animal practitioner when:

• Clinical signs progress despite competently delivered combination therapy (enrofloxacin + doxycycline at appropriate doses for at least 4 weeks) plus adjunctive support and husbandry correction.
• Imaging suggests a focal mass, cranial mediastinal lesion, or pulmonary abscess warranting CT or cytologic/surgical workup.
• Vestibular signs are profound, fluctuant, or accompanied by other cranial-nerve deficits suggesting a process beyond M. pulmonis otitis interna (consider pituitary adenoma).
• Multiple rats in a household are affected and colony-level intervention is desired.
• Advanced diagnostics (BAL cytology, CT, echocardiography) are requested and outside the practice's capability.

Where exotic referral is geographically unavailable, telemedicine consultation with a rodent-experienced clinician is increasingly appropriate.

Key references

• Quesenberry KE, Mans C, Orcutt CJ, Carpenter JW (eds.). Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 4th ed. Elsevier; 2021. (Chapters on rat clinical medicine and respiratory disease.)
• Carpenter JW, Harms CA (eds.). Carpenter's Exotic Animal Formulary. 6th ed. Elsevier; 2022. (Rodent antimicrobial, NSAID, and bronchodilator dose tables.)
• Mitchell MA, Tully TN (eds.). Manual of Exotic Pet Practice. Saunders Elsevier; 2009. (Rodent respiratory disease chapter.)
• Keeble E, Meredith A (eds.). BSAVA Manual of Rodents and Ferrets. BSAVA; 2009. (Rat medicine and husbandry.)
• Percy DH, Barthold SW. Pathology of Laboratory Rodents and Rabbits. 4th ed. Wiley-Blackwell; 2013. (Pathogenesis of M. pulmonis; co-pathogens; pulmonary neoplasia.)
• National Research Council (US) Committee on Infectious Diseases of Mice and Rats. Infectious Diseases of Mice and Rats. National Academies Press; 1991. (Foundational text on MRM, Sendai virus, CAR bacillus, Streptococcus pneumoniae, Corynebacterium kutscheri.)
• Schoeb TR. "Respiratory diseases of rodents." Vet Clin North Am Exot Anim Pract. 2000;3(2):481–496.
• Pritchett-Corning KR, Cosentino J, Clifford CB. "Contemporary prevalence of infectious agents in laboratory mice and rats." Lab Anim. 2009;43(2):165–173.
• Lennox AM. "Respiratory disease and pasteurellosis." In: Ferrets, Rabbits, and Rodents. (And related rodent medicine review articles.)
• Mayer J, Donnelly TM (eds.). Clinical Veterinary Advisor: Birds and Exotic Pets. Elsevier; 2013. (Quick-reference rodent respiratory entries.)

Disclaimer: This article is a clinical reference for licensed veterinary professionals. Doses are drawn from published exotic-animal formularies and peer-reviewed sources current at the time of writing; individual patient factors (age, body condition, concurrent disease, compounded formulation) may require dose adjustment. ExoticRx does not replace clinical judgment, the prescribing veterinarian's drug-label review, or consultation with a board-certified specialist when indicated. Off-label and extralabel drug use must comply with applicable regional regulations (e.g., AMDUCA in the United States). This material is not intended for use by pet owners as a substitute for veterinary care.